Viron Molecular Medicine Institute

Viron Molecular Medicine Institute (VMMI) is a biotechnology company dedicated to the development of next-generation vaccines and therapeutic agents for infectious diseases and oncology. The company utilizes a proprietary viral vector platform designed to enhance immune responses and improve the safety profile of its candidates compared to traditional methods. Its lead program, VMMI-01, is a vaccine candidate targeting SARS-CoV-2, developed to provide robust protection against emerging variants. VMMI aims to address unmet medical needs by combining cutting-edge molecular medicine with efficient, scalable manufacturing processes. The institute is led by industry veterans, including Dr. Farshad Guirakhoo, who has a proven track record in global vaccine development and regulatory success. Beyond COVID-19, the company is exploring the application of its technology in universal influenza vaccines and immuno-oncology treatments.